BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 30662341)

  • 1. Nonselective Cyclooxygenase Inhibition Retards Cyst Progression in a Murine Model of Autosomal Dominant Polycystic Kidney Disease.
    Zhang M; Srichai MB; Zhao M; Chen J; Davis LS; Wu G; Breyer MD; Hao CM
    Int J Med Sci; 2019; 16(1):180-188. PubMed ID: 30662341
    [No Abstract]   [Full Text] [Related]  

  • 2. Cyclooxygenase 2 inhibition slows disease progression and improves the altered renal lipid mediator profile in the Pkd2
    Monirujjaman M; Aukema HM
    J Nephrol; 2019 Jun; 32(3):401-409. PubMed ID: 30671914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice.
    Amura CR; Brodsky KS; Groff R; Gattone VH; Voelkel NF; Doctor RB
    Am J Physiol Cell Physiol; 2007 Jul; 293(1):C419-28. PubMed ID: 17475663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct patterns of kidney and liver cyst growth in pkd2(WS25/-) mice.
    Doctor RB; Serkova NJ; Hasebroock KM; Zafar I; Edelstein CL
    Nephrol Dial Transplant; 2010 Nov; 25(11):3496-504. PubMed ID: 20388629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease.
    Masyuk TV; Radtke BN; Stroope AJ; Banales JM; Masyuk AI; Gradilone SA; Gajdos GB; Chandok N; Bakeberg JL; Ward CJ; Ritman EL; Kiyokawa H; LaRusso NF
    Gastroenterology; 2012 Mar; 142(3):622-633.e4. PubMed ID: 22155366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haploinsufficiency of Pkd2 is associated with increased tubular cell proliferation and interstitial fibrosis in two murine Pkd2 models.
    Chang MY; Parker E; Ibrahim S; Shortland JR; Nahas ME; Haylor JL; Ong AC
    Nephrol Dial Transplant; 2006 Aug; 21(8):2078-84. PubMed ID: 16720597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease.
    Spirli C; Mariotti V; Villani A; Fabris L; Fiorotto R; Strazzabosco M
    J Hepatol; 2017 Mar; 66(3):571-580. PubMed ID: 27826057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model.
    Pastor-Soler NM; Li H; Pham J; Rivera D; Ho PY; Mancino V; Saitta B; Hallows KR
    Am J Physiol Renal Physiol; 2022 Jan; 322(1):F27-F41. PubMed ID: 34806449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic Cysts in Autosomal Dominant Polycystic Kidney Disease: Prevalence and Association with PKD2 Gene Mutations.
    Kim JA; Blumenfeld JD; Chhabra S; Dutruel SP; Thimmappa ND; Bobb WO; Donahue S; Rennert HE; Tan AY; Giambrone AE; Prince MR
    Radiology; 2016 Sep; 280(3):762-70. PubMed ID: 27046073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PKD2-Related Autosomal Dominant Polycystic Kidney Disease: Prevalence, Clinical Presentation, Mutation Spectrum, and Prognosis.
    Cornec-Le Gall E; Audrézet MP; Renaudineau E; Hourmant M; Charasse C; Michez E; Frouget T; Vigneau C; Dantal J; Siohan P; Longuet H; Gatault P; Ecotière L; Bridoux F; Mandart L; Hanrotel-Saliou C; Stanescu C; Depraetre P; Gie S; Massad M; Kersalé A; Séret G; Augusto JF; Saliou P; Maestri S; Chen JM; Harris PC; Férec C; Le Meur Y
    Am J Kidney Dis; 2017 Oct; 70(4):476-485. PubMed ID: 28356211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease.
    Zafar I; Ravichandran K; Belibi FA; Doctor RB; Edelstein CL
    Kidney Int; 2010 Oct; 78(8):754-61. PubMed ID: 20686448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibiting the HSP90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney disease.
    Seeger-Nukpezah T; Proia DA; Egleston BL; Nikonova AS; Kent T; Cai KQ; Hensley HH; Ying W; Chimmanamada D; Serebriiskii IG; Golemis EA
    Proc Natl Acad Sci U S A; 2013 Jul; 110(31):12786-91. PubMed ID: 23858461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyst formation in kidney via B-Raf signaling in the PKD2 transgenic mice.
    Park EY; Sung YH; Yang MH; Noh JY; Park SY; Lee TY; Yook YJ; Yoo KH; Roh KJ; Kim I; Hwang YH; Oh GT; Seong JK; Ahn C; Lee HW; Park JH
    J Biol Chem; 2009 Mar; 284(11):7214-22. PubMed ID: 19098310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial Abnormality Facilitates Cyst Formation in Autosomal Dominant Polycystic Kidney Disease.
    Ishimoto Y; Inagi R; Yoshihara D; Kugita M; Nagao S; Shimizu A; Takeda N; Wake M; Honda K; Zhou J; Nangaku M
    Mol Cell Biol; 2017 Dec; 37(24):. PubMed ID: 28993480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human polycystin-2 transgene dose-dependently rescues ADPKD phenotypes in Pkd2 mutant mice.
    Li A; Tian X; Zhang X; Huang S; Ma Y; Wu D; Moeckel G; Somlo S; Wu G
    Am J Pathol; 2015 Oct; 185(10):2843-60. PubMed ID: 26435415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triptolide reduces cyst formation in a neonatal to adult transition Pkd1 model of ADPKD.
    Leuenroth SJ; Bencivenga N; Chahboune H; Hyder F; Crews CM
    Nephrol Dial Transplant; 2010 Jul; 25(7):2187-94. PubMed ID: 20139063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ouabain enhances renal cyst growth in a slowly progressive mouse model of autosomal dominant polycystic kidney disease.
    Trant J; Sanchez G; McDermott JP; Blanco G
    Am J Physiol Renal Physiol; 2023 Dec; 325(6):F857-F869. PubMed ID: 37823195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probenecid slows disease progression in a murine model of autosomal dominant polycystic kidney disease.
    Arkhipov SN; Potter DL; Sultanova RF; Ilatovskaya DV; Harris PC; Pavlov TS
    Physiol Rep; 2023 Apr; 11(7):e15652. PubMed ID: 37024297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quercetin inhibits renal cyst growth in vitro and via parenteral injection in a polycystic kidney disease mouse model.
    Zhu Y; Teng T; Wang H; Guo H; Du L; Yang B; Yin X; Sun Y
    Food Funct; 2018 Jan; 9(1):389-396. PubMed ID: 29215110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1/cyclin axis.
    Li A; Fan S; Xu Y; Meng J; Shen X; Mao J; Zhang L; Zhang X; Moeckel G; Wu D; Wu G; Liang C
    J Cell Mol Med; 2017 Aug; 21(8):1619-1635. PubMed ID: 28244683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.